FMP
NASDAQ
17.06 USD
-0.09 (-0.528%)
Dr. Steven A. Nichtberger M.D.
Healthcare
Biotechnology
https://www.cabalettabio.com
NASDAQ
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage...
0001759138
US12674W1099
12674W109
2929 Arch Street
267 759 3100
US
101
Oct 25, 2019
0001759138
NASDAQ
Biotechnology
Healthcare
12674W109
US12674W1099
US
17.06
2.46
918.96k
823M
-
6.94-26.35
4.6
-
-
-
-
-10.34
-
https://www.cabalettabio.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.